Pancreatic Cancer Research

ResearcherQingdao UniversityActive in the last 2 years

Jianjun Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6138-4472; OpenAlex author ID A5069915515. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
31
Papers, trials and grants by year

2022: 1 paper · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 7

  1. Daraxonrasib: The first-in-class RAS(ON) multi-selective inhibitor approved for treatment of metastatic pancreatic adenocarcinoma. Last author DOI 10.5582/ddt.2026.01067↗
  2. MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Co-author DOI 10.1093/carcin/bgae025↗
  3. Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.89788↗
  4. Exosomal miRNAs in the microenvironment of pancreatic cancer. Co-author DOI 10.1016/j.cca.2023.117360↗
  5. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Co-author DOI 10.1126/sciadv.add6995↗
  6. Tertiary lymphoid structures in pancreatic cancer: a new target for immunotherapy. Co-author DOI 10.3389/fimmu.2023.1222719↗
  7. The Second-Generation Proteasome Inhibitor Ixazomib Enhances the Anticancer Effects of Gemcitabine or Fluorouracil in Pancreatic Cancer Cells Co-author DOI 10.21203/rs.3.rs-1374979/v1↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xinlei Zou · 3 shared papers, 2023–2024 · strength 0.57
  2. Yunfu Cui · 3 shared papers, 2023–2024 · strength 0.57
  3. Xiangyu Zhong · 3 shared papers, 2022–2023 · strength 0.57
  4. Yueyi Sun · 1 shared paper, 2026 · strength 0.50
  5. Nader N Hanna · 1 shared paper, 2024 · strength 0.18
  6. Subrata Sen · 1 shared paper, 2024 · strength 0.18
  7. Michael B. Ghadimi · 1 shared paper, 2024 · strength 0.18
  8. Jochen Gaedcke · 1 shared paper, 2024 · strength 0.18
  9. Yuuki Ohara · 1 shared paper, 2024 · strength 0.18
  10. S. S. Yang · 1 shared paper, 2024 · strength 0.18
  11. Azadeh Azizian · 1 shared paper, 2024 · strength 0.18
  12. Nagireddy Putluri · 1 shared paper, 2024 · strength 0.18
  13. S. Perwez Hussain · 1 shared paper, 2024 · strength 0.18
  14. Yi Xu · 1 shared paper, 2023 · strength 0.18
  15. Haolin Bao · 1 shared paper, 2024 · strength 0.18
  16. Xiangyu Zhong · 1 shared paper, 2024 · strength 0.18
  17. Wenjing Sun · 1 shared paper, 2022 · strength 0.17
  18. Dongsheng Wang · 1 shared paper, 2022 · strength 0.17
  19. Hao Wang · 1 shared paper, 2022 · strength 0.17
  20. David R Piwnica-Worms · 1 shared paper, 2023 · strength 0.12
  21. Wei Hu · 1 shared paper, 2023 · strength 0.12
  22. Youqiong Ye · 1 shared paper, 2023 · strength 0.12
  23. Cheng‐Cao Sun · 1 shared paper, 2023 · strength 0.12
  24. Liuqing Yang · 1 shared paper, 2023 · strength 0.12
  25. Jun Yao · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.